Cold sores may play role in Alzheimer's development, new research reveals
Researchers examined 344,628 "case-control pairs." The pairs were matched in age, sex, geographical region and number of healthcare visits — but one had Alzheimer's disease and one did not.
Of the groups studied, 1,507 people with Alzheimer's also had herpes simplex virus type 1 (HSV-1), which is the most common cause of cold sores. Only 823 people in the control group had HSV-1.
First Blood Test For Alzheimer's Diagnosis Cleared By Fda
Among these 2,330 people, 40% used anti-herpetic medication following their diagnosis.
Those who were treated for the virus were 17% less likely to develop Alzheimer's disease than those who didn't use the treatments, the study found.
Read On The Fox News App
The risk of developing this form of dementia is known to rise with age. However, the chance of an HSV-1 diagnosis was 80% higher in those diagnosed with Alzheimer's, according to the research.
Less commonly, cold sores can be caused by herpes simplex virus type 2 (HSV-2).
Alzheimer's Disease Could Be Prevented By Antiviral Drug Already On Market
The analysis places "an even greater emphasis on viewing the prevention of herpes viruses as a public health priority," the researchers said in a press release.
Overall, women made up 65% of the Alzheimer's cases. Their average age was 73, and they tended to have more co-existing conditions, which were all risk factors.
The study also observed the potential role of other herpes viruses, some of which were associated with an elevated risk of Alzheimer's disease.
The specific connection between viruses like HSV-1 and heightened dementia risk isn't clear, the researchers noted.
Click Here To Sign Up For Our Health Newsletter
"However, studies have shown that inflammatory alterations in the brain caused by HSV infection are pivotal in [Alzheimer's disease] development," they said in the release.
Treatment with anti-viral therapy seems to lower the risk of Alzheimer's, "suggesting that HSV-1 treatment may be protective," the study says.
"There's no cure for cold sores, but treatment can help manage outbreaks," according to Mayo Clinic.
"Prescription antiviral medicine or creams can help sores heal more quickly. And they may make future outbreaks happen less often and be shorter and less serious."
There were some limitations in the study, the researchers acknowledged.
"Due to limited data history, HSV-1 infections prior to the patient's database entry were not included in the analysis, and it is possible that some overlap exists between HSV-1 and HSV-2 diagnoses," the researchers noted.
"Additionally, many individuals with HSV-1 infection are asymptomatic, and others may not seek medical care during recurrences and are therefore not clinically diagnosed and recorded in the database."
While an estimated two-thirds of people under 50 are infected with HSV-1, data on symptomatic infections is limited, "as manifestations can be mild or unnoticed," the researchers added.
For more Health articles, visit www.foxnews.com/health
Under-diagnosis of Alzheimer's disease could also skew the results.
Fox News Digital reached out to the researchers and other doctors for comment.Original article source: Cold sores may play role in Alzheimer's development, new research reveals
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Epoch Times
5 hours ago
- Epoch Times
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.
Yahoo
7 hours ago
- Yahoo
Wife Shares 1 Thing She, Husband Refuse to Give Up After He's Diagnosed with Early-Onset Alzheimer's at 55 (Exclusive)
Despite a devastating Alzheimer's diagnosis, one couple refuses to give up on their love for adventure and each other NEED TO KNOW Anthony and Karen Sandone are avid travelers who tied the knot in Punta Cana in June 2009 In 2023, Anthony was diagnosed with early-onset Alzheimer's In the last two years, Anthony's condition has progressed "to moderate/severe," but that hasn't stopped them from enjoying time together abroad What began as occasional forgetfulness slowly turned into persistent memory and language issues that couldn't be ignored for Anthony Sandone. Concerned, Sandone and his wife, Karen, began seeking answers in March 2022, visiting numerous doctors in search of an explanation. Due to Anthony's age and overall good health, dementia wasn't initially suspected, and the process of ruling out other conditions was long and emotionally exhausting. By May 2023, Anthony was forced to retire from his 35-year career in chemical sales due to his progressing symptoms. Four months later, on Sept. 7, 2023, their suspicions were confirmed. Anthony was diagnosed with early-onset Alzheimer's at just 55 years old – changing their life forever. Anthony, now 57, lives with a form of the disease called primary progressive aphasia, which severely affects his ability to speak and understand language. Once the picture of vitality – he, a former collegiate athlete, and Karen, a former Philadelphia Eagles cheerleader – truly believed they would be the couple to ride out the disease until there was a cure. They even enlisted support from Mano Wellness, a health coaching platform, to help Anthony maintain his fitness, diet, and nutrition. But Alzheimer's had other plans. 'In less than two years, Anthony's condition has progressed from mild/moderate to moderate/severe and there is no one in control of this progression but Alzheimer's,' Karen, 58, tells PEOPLE exclusively. Conversations, remembering names, and even everyday tasks like using a phone or remote control are a struggle. Following instructions is difficult, so Karen limits his tasks and ensures those around him are patient and help guide him through the confusion. 'It was heartbreaking to tell Anthony he could no longer drive,' Karen recalls of a turning point in November 2024. 'A moment that made him feel like everything was being taken from him.' As his condition progressed, so did the impact on their blended family of six adult children. Anthony struggles with short-term memory, making unfamiliar places and sudden changes to his routine especially difficult and stressful. He can no longer use electronic devices like phones, so Karen has taken on full responsibility for managing everything – appointments, finances, and household needs – while also working full-time and serving as his primary caregiver. While he once handled all their travel planning, from booking flights to organizing cruise itineraries, it's been an emotional adjustment for Karen to take on the extra tasks. 'The little things,' she says, are what she misses most – things she realizes she once took for granted and that are no longer possible for him. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Yet despite these challenges, Karen and Anthony have made a conscious choice not to let the disease stop them from living. Travel, a passion they've shared for years, especially after becoming empty nesters, continues to be a cornerstone of their time together. Their favorite destinations include Puerto Vallarta, Hawaii, the Caribbean, and their most unforgettable trips – Italy and Greece. Cruises, however, have proven to be the most manageable type of travel given Anthony's current needs. 'He did really well on the most recent cruise and the crew team was very helpful,' Karen reveals. To make travel safer and more comfortable, Karen upgraded their cabin to an enclosed room with private amenities, informed the cruise staff of Anthony's condition, and equipped him with a dementia ID lanyard and a medical-alert Apple Watch. 'I was scared,' she admits. 'People discouraged me from going alone with Anthony.' Still, she stayed by his side the entire time. They laughed and soaked in every moment. Even with the repeated questions, the confusion, and the difficulty communicating, they found joy in the little things that matter most: simply being together. 'I do not know if that was our last trip together. But I have no regrets,' she tells PEOPLE. Karen refuses to let fear dictate their life choices. She almost canceled their most recent trip, but after being asked if she would regret not going, her answer was 'yes.' That moment shifted everything. Beyond their personal journey, the couple has become powerful advocates in their community. Karen recently represented the Alzheimer's Impact Movement (AIM) in Washington, D.C. as a Congressional Advocate, where she traveled to Capitol Hill to raise awareness about the importance of continued funding for Alzheimer's research and support. Her advice for other couples facing Alzheimer's is simple but profound: 'Meet your loved one where they are, in the moment.' Alzheimer's, without a doubt, has transformed their marriage. And although Anthony is no longer the person he once was, he is still Karen's husband and best friend, and the pair try to cherish every moment they share together. Read the original article on People Solve the daily Crossword
